Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
1997-10-20
2002-07-23
Eyler, Yvonne (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C435S007200, C435S007800, C435S069100, C435S007210, C435S007240, C435S174000, C435S005000, C530S300000, C530S350000, C530S351000, C424S143100
Reexamination Certificate
active
06423501
ABSTRACT:
BACKGROUND OF THE INVENTION
In the past two decades, tremendous advances have been made in understanding the molecular mechanisms used by various types of cell surface receptors to transduce signals. Nearly all of these advances have come from the study of model systems where a receptor “activates” cells to generate a well-defined response. As knowledge about activating model systems has increased, it has become clear that there are many situations in which the activating signal sent from one receptor is modulated as the direct result of a negative or inhibitory signal sent by another cell surface receptor. While the study of this type of signaling is generally in its infancy, several recent studies have begun to shed light on the molecular mechanisms which underlie receptor-mediated inhibitory signals in immunologic systems. Given the tendency of nature to utilize signaling functions modularly in a variety of signaling pathways, the paradigms outlined by these systems may have implications for the study of inhibitory or deactivating signals in non-immunologic situations as well. In addition, the study of these signals may add new dimensions to the understanding of other widely utilized signaling pathways.
SUMMARY OF THE INVENTION
As described herein, monoclonal antibodies (mAbs) have been isolated which inhibit Fc&egr;RI-induced mast cell degranulation. Through protein isolation, peptide sequencing, cloning, and gene expression, CD81 has been identified as a novel inhibitory receptor for Fc&egr;RI and Fc&ggr;RIII. Anti-CD81 mAbs also inhibited passive cutaneous anaphylaxis (PCA) reactions, a model of IgE-dependent, mast cell activation in vivo.
The invention pertains to a method of inhibiting cell surface receptor-mediated signaling comprising contacting a cell with an agent which induces CD81-mediated signal transduction. In a particular embodiment, the cell surface receptor is selected from the group consisting of Fc&egr;RI and Fc&ggr;RIII. In one embodiment, the method is a calcium independent method.
The invention also relates to a method of inhibiting degranulation comprising contacting a cell with an agent which induces CD81-mediated signal transduction. In one embodiment, degranulation is mediated by the Fc&egr;RI receptor. In another embodiment, the method is a calcium independent method.
The invention further relates to a calcium independent method of inhibiting cell surface receptor-mediated signaling in a mammal, such as a human, comprising administering to the mammal an effective amount of an agent which induces CD81-mediated signal transduction. In one embodiment, the cell surface receptor is selected from the group consisting of Fc&egr;RI and Fc&ggr;RIII.
The invention also pertains to a method, e.g., a calcium independent method, of inhibiting degranulation induced by a cell surface receptor-mediated signal in a mammal, such as a human, comprising administering to the mammal an effective amount of an agent which induces CD81-mediated signal transduction.
The invention further pertains to a method of treating (e.g., preventing or reducing the severity of) an allergic condition in a mammal, such as a human, comprising administering to the mammal an effective amount of an agent which induces CD81-mediated signal transduction. In particular embodiments, the allergic condition is asthma, hay fever or atopic eczema.
The invention also relates to a calcium independent method of enhancing cell surface receptor-mediated signaling, e.g., Fc&egr;RI-mediated signaling and Fc&ggr;RIII-mediated signaling, comprising contacting a cell with an agent which inhibits CD81-mediated signal transduction.
The invention also pertains to a calcium-independent method of enhancing degranulation comprising contacting a cell with an agent which inhibits CD81-mediated signal transduction. For example, degranulation can be mediated by the Fc&egr;RI receptor. The invention also relates to a calcium independent method of enhancing cell surface receptor-mediated signaling in a mammal comprising administering to the mammal an effective amount of an agent which inhibits CD81-mediated signal transduction.
The invention further relates to an assay for identifying agents which alter CD81-mediated signal transduction, comprising combining a cell bearing CD81 with an agent to be tested, under conditions suitable for CD81-mediated signal transduction, and determining the level of CD81-mediated signal transduction. If the level of CD81-mediated signal transduction is altered relative to a control, the agent alters CD81-mediated signal transduction. In a particular embodiment, the agent is one which enhances or induces CD81-mediated signal transduction.
The invention also relates to an assay for identifying agents which alter calcium independent CD81-mediated regulation of cell surface receptor signaling, comprising combining a cell bearing CD81 and an appropriate cell surface receptor with an agent which alters CD81-mediated signal transduction under conditions suitable for signal transduction by CD81 and the cell surface receptor, and determining the level of cell surface receptor signaling. If the level of cell surface receptor signaling is altered relative to a control, the agent alters calcium independent CD81-mediated regulation of cell surface receptor signaling.
REFERENCES:
Jouvin, M-H.E., et al., “Differential Control of the Tyrosine Kinases Lyn and Syk by the Two Signaling Chains of the High Affinity Immunoglobulin E Receptor”,The Journal of Biological Chemistry,269(8):5918-5925 (1994).
Penhallow, R.C., et al., “Temporal Activation of Nontransmembrane Protein-Tyrosine Kinases Following Mast Cell Fc&egr;RI Engagement”,The Journal of Biological Chemistry,270(40):23362-23365 (1995).
Scharenberg, A.M., et al., “Reconstitution of Interactions Between Tyrosine Kinases and the High Affinity IgE Receptor Which Are Controlled by Receptor Clustering”,The EMBO Journal,14(14):3385-3394 (1995).
Lin, S., et al., “The Fc&egr;RI&bgr; Subunit Functions as an Amplifier of Fc&egr;RI&ggr;-Mediated Cell Activation Signals”,Cell,85:985-995 (1996).
Paul, W.E., et al., “Lymphokine and Cytokine Production by Fc&egr;RI+Cells”,Advances in Immunology,53:1-29 (1993).
Scharenberg, A.M. and Kinet, J-P., “Early Events in Mast Cell Signal Transduction”,Chem. Immunol.,61:72-87 (1995).
Ravetch, J.V. and Kinet, J-P., “Fc Receptors”,Annu. Rev. Immunol. 9:457-492 (1991).
Shaw, A.S., et al., “Interactions of TCR Tyrosine Based Activation Motifs with Tyrosine Kinases”,Immunology,7:13-20 (1995).
Choi, O.H., et al., “Calcium Mobilization via Sphingosine Kinase in Signalling by the Fc&egr;RI Antigen Receptor”,Nature,380:634-636 (1996).
Guthmann, M.D., et al., “A Secretion Inhibitory Signal Transduction Molecule on Mast Cells is Another C-Type Lectin”,Proc. Natl. Acad. Sci.,92:9397-9401 (1995).
Katz, H.R., et al., “Mouse Mast Cell gp49B1 Contains Two Immunoreceptor Tyrosine-Based Inhibition Motifs and Suppresses Mast Cell Activation When Coligated with the High-Affinity Fc Receptor for IgE”,Proc. Natl. Acad. Sci.,93:10809-10814 (1996).
Wright, M.D. and Tomlinson, M.G., “The Ins and Outs of the Transmembrane 4 Superfamily”,Immunology Today,15(12):588-594(1994).
Fearon, D.T. and Carter, R.H., “The CD19/CR2/TAPA-1 Complex of B Lymphocytes: Linking Natural to Acquired Immunity”,Annu Rev. Immunol. 13:127-149 (1995).
Secrist, H., et al., “Ligation of TAPA-1 (CD81) or Major Histocompatibility Complex Class II in Co-Cultures of Human B and T Lymphocytes Enhances Interleukin-4 Synthesis by Antigen-Specific CD4+T Cells”,Eur. J. Immunol.,26:1435-1442 (1996).
Todd, S.C., et al., “CD81 Expressed on Human Thymocytes Mediates Integrin Activation and Interleukin 2-Dependent Proliferation”,J. Exp. Med.,184:2055-2060 (1996).
Oren, R., et al., “TAPA-1, the Target of an Antiproliferative Antibody, Defines a New Family of Transmembrane Proteins”,Molecular and Cellular Biology,10(8):4007-4015 (1990).
Boismenu, R., et al., “A Role for CD81 in Early T Cell Development”,Science,271:198-200 (1996).
Imai, T., et al., “Molecular Analyses of the Associa
Fleming Tony
Kinet Jean-Pierre
Basi Nirmal S.
Beth Israel Deaconess Medical Center
Eyler Yvonne
Hamilton Brook Smith & Reynolds P.C.
LandOfFree
Calcium-independent negative regulation by CD81 of receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Calcium-independent negative regulation by CD81 of receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Calcium-independent negative regulation by CD81 of receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2916281